» Articles » PMID: 32931760

The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective

Overview
Journal Am J Med
Specialty General Medicine
Date 2020 Sep 15
PMID 32931760
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disease worldwide, with rising rates in parallel to those of obesity, type 2 diabetes, and metabolic syndrome. NAFLD encompasses a wide spectrum of pathology from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis, which are linked to poor outcomes. Studies confirm a significant amount of undiagnosed NAFLD and related fibrosis within the community, increasing the overall burden of the disease. NAFLD appears to be more prevalent in certain populations, such as those with type 2 diabetes and metabolic syndrome. Early detection and lifestyle modifications, including weight loss and regular exercise, have been shown to improve outcomes. Adverse cardiovascular events are a key contributor to NAFLD-associated morbidity and mortality, and efforts to minimize their occurrence are essential. A targeted and algorithmic approach using noninvasive diagnostic techniques is promptly required to identify and risk-stratify patients with NAFLD. Patients at low risk of progression to NASH and advanced fibrosis can be managed in the primary care setting, while those at high risk of disease progression should be referred to hepatology specialists for surveillance and treatment. This review summarizes the key data of NAFLD's impact within primary care populations and proposes a potential algorithmic approach to identifying and managing such patients.

Citing Articles

High-Fat Diet Delays Liver Fibrosis Recovery and Promotes Hepatocarcinogenesis in Rat Liver Cirrhosis Model.

Taguchi D, Shirakami Y, Sakai H, Maeda T, Miwa T, Kubota M Nutrients. 2024; 16(15).

PMID: 39125385 PMC: 11314319. DOI: 10.3390/nu16152506.


Can Nutraceuticals Support the Treatment of MASLD/MASH, and thus Affect the Process of Liver Fibrosis?.

Sokal-Dembowska A, Jarmakiewicz-Czaja S, Ferenc K, Filip R Int J Mol Sci. 2024; 25(10).

PMID: 38791276 PMC: 11120776. DOI: 10.3390/ijms25105238.


IL-27 increases energy storage in white adipocytes by enhancing glucose uptake and fatty acid esterification.

Scaffidi C, Srdic A, Konrad D, Wueest S Adipocyte. 2023; 12(1):2276346.

PMID: 37948192 PMC: 10773535. DOI: 10.1080/21623945.2023.2276346.


The Association of Nonalcoholic Fatty Liver Disease With Neutrophil-to-Lymphocyte Ratio and Neutrophil-Percentage-to-Albumin Ratio.

Cucoranu D, Pop M, Niculescu R, Kosovski I, Toganel R, Licu R Cureus. 2023; 15(6):e41197.

PMID: 37525801 PMC: 10387286. DOI: 10.7759/cureus.41197.


Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis.

Xue H, Xing H, Wang B, Fu C, Zhang Y, Qiao X Drug Des Devel Ther. 2023; 17:1417-1432.

PMID: 37197367 PMC: 10184894. DOI: 10.2147/DDDT.S404055.